Loading clinical trials...

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer

NCT00319254•Pfizer

Summary

The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Stage IIIB, IIIC or IV breast cancer not curable with available therapy.
•Patients must have progressed after 1 but not more than 3 prior chemotherapy regimens.
•Life expectancy of at least 16 weeks.
•Ability to swallow whole capsules.

Exclusion Criteria

•Use of or requirement for bisphosphonates within 8 weeks prior to screening.
•Any other cancer within 5 years of screening, except for basal cell carcinoma or cervical carcinoma in situ
•Uncontrolled cardiac disease including congestive heart failure, angina, heart attack, etc.
•Recent or ongoing significant gastrointestinal disorder

Locations (15)

Pfizer Investigational Site

Duarte, California, United States

Pfizer Investigational Site

Santa Monica, California, United States

Pfizer Investigational Site

Tampa, Florida, United States

Pfizer Investigational Site

Cleveland, Ohio, United States

Pfizer Investigational Site

Darlinghurst, New South Wales, Australia

Pfizer Investigational Site

Dijon, France

Pfizer Investigational Site

Saint-Herblain, France

Pfizer Investigational Site

Pokfulam, Hong Kong

Pfizer Investigational Site

Floriana, Malta

Pfizer Investigational Site

Lodz, Poland

Key Dates

Start Date

May 1, 2006

Primary Completion Date

February 1, 2009

Completion Date

February 1, 2009

Last Updated

January 31, 2013

Enrollment

ACTUAL participants

Conditions

Breast NeoplasmsNeoplasm Metastasis

Interventions

SKI-606 (Bosutinib)

DRUG

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITING

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Inclusion Criteria

Exclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients

A Study of LY4175408 in Participants With Advanced Cancer